Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/Hims settles lawsuit with Novo Nordisk, unlocking 98% growth potential.

HIMS

$37.05

+$1.90 +5.41%

Hims settles lawsuit with Novo Nordisk, unlocking 98% growth potential.

Analyst Insights

25 Mar 2026

Seeking Alpha

View Source

Bullish

Hims has resolved its legal dispute with Novo Nordisk, removing a significant obstacle that previously limited its ability to offer branded drugs. Despite this positive development, Hims' stock valuations have yet to rebound to pre-lawsuit levels due to ongoing insider selling and changes in disclosure practices. Analysts believe the market underestimates Hims' growth potential driven by increasing subscribers, product sustainability, and expansion into new markets. This resolution and growth outlook suggest nearly 98% upside potential for Hims in the medium term as valuations normalize.

More News (HIMS)

Law firm investigates Hims & Hers for allegedly sharing users' private health data without consent.

Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...

Market News

Bearish

7 hours ago